SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-054488
Filing Date
2021-11-04
Accepted
2021-11-04 16:13:02
Documents
14
Period of Report
2021-11-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kura-8k_20211104.htm   iXBRL 8-K 39079
2 EX-99.1 kura-ex991_6.htm EX-99.1 166681
3 GRAPHIC gwflankmo4jk000001.jpg GRAPHIC 11315
  Complete submission text file 0001564590-21-054488.txt   361890

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA kura-20211104.xsd EX-101.SCH 5701
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE kura-20211104_lab.xml EX-101.LAB 19326
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kura-20211104_pre.xml EX-101.PRE 11498
7 EXTRACTED XBRL INSTANCE DOCUMENT kura-8k_20211104_htm.xml XML 3553
Mailing Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130
Business Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130 (858) 500-8800
Kura Oncology, Inc. (Filer) CIK: 0001422143 (see all company filings)

IRS No.: 611547851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37620 | Film No.: 211380097
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences